308.81
-10.25 (-3.21%)
| Previous Close | 319.06 |
| Open | 307.48 |
| Volume | 560,364 |
| Avg. Volume (3M) | 256,166 |
| Market Cap | 34,172,278,784 |
| Price / Earnings (TTM) | 605.51 |
| Price / Earnings (Forward) | 39.37 |
| Price / Sales | 7.18 |
| Price / Book | 8.60 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | -9.40% |
| Operating Margin (TTM) | 0.99% |
| Diluted EPS (TTM) | -3.69 |
| Quarterly Revenue Growth (YOY) | 48.60% |
| Total Debt/Equity (MRQ) | 28.49% |
| Current Ratio (MRQ) | 1.96 |
| Operating Cash Flow (TTM) | 212.02 M |
| Levered Free Cash Flow (TTM) | -120.68 M |
| Return on Assets (TTM) | -3.22% |
| Return on Equity (TTM) | -11.44% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | BeOne Medicines Ltd. | Bullish | - |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.50 |
|
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne’s revenue. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 17.31% |
| % Held by Institutions | 43.94% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Capital International, Inc./Ca/ | 30 Sep 2025 | 325,844 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 408.00 (RBC Capital, 32.12%) | Buy |
| Median | 396.00 (28.23%) | |
| Low | 383.00 (Morgan Stanley, 24.02%) | Buy |
| Average | 394.57 (27.77%) | |
| Total | 7 Buy | |
| Avg. Price @ Call | 336.91 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 24 Nov 2025 | 400.00 (29.53%) | Buy | 332.71 |
| RBC Capital | 18 Nov 2025 | 408.00 (32.12%) | Buy | 363.92 |
| 07 Nov 2025 | 395.00 (27.91%) | Buy | 319.97 | |
| Citigroup | 10 Nov 2025 | 405.00 (31.15%) | Buy | 329.20 |
| Citizens | 07 Nov 2025 | 396.00 (28.23%) | Buy | 319.97 |
| Morgan Stanley | 20 Oct 2025 | 383.00 (24.02%) | Buy | 318.59 |
| JP Morgan | 08 Oct 2025 | 385.00 (24.67%) | Buy | 351.09 |
| Barclays | 18 Sep 2025 | 385.00 (24.67%) | Buy | 342.89 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |